21.35 USD
-0.4 (-1.84%)
22.4889 USD
+1.14 (+5.33%)
ChartMill assigns a Buy % Consensus number of 46% to AKTS. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 0.26. This target is -98.81% below the current price.
- AKTS was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about AKTS.
- In the last month the buy percentage fell by 32 points. So the trust of analysts is decreasing.
- AKTS was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-01-04 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-09-07 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-09-07 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2023-05-09 | Roth MKM | Maintains | Buy |
| 2023-05-09 | Oppenheimer | Maintains | Outperform |
| 2023-01-24 | B. Riley Securities | Initiate | Buy |
| 2022-11-15 | Oppenheimer | Maintains | Outperform |
| 2022-09-13 | Piper Sandler | Maintains | Overweight |
| 2022-05-03 | Piper Sandler | Maintains | Overweight |
| 2021-11-02 | Oppenheimer | Maintains | Outperform |
| 2021-05-04 | Roth Capital | Maintains | Buy |
AKTIS ONCOLOGY INC / AKTS FAQ
What is the average price target for AKTIS ONCOLOGY INC (AKTS) stock?
7 analysts have analysed AKTS and the average price target is 0.26 USD. This implies a price decrease of -98.81% is expected in the next year compared to the current price of 21.35.
What is the consensus rating for AKTS stock?
The consensus rating for AKTIS ONCOLOGY INC (AKTS) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.